10 Biggest Price Target Changes For Friday
Piper Sandler boosted the price target for Moderna, Inc. (NASDAQ: MRNA) from $246 to $445. Moderna shares fell 1.6% to $409.55 in pre-market trading.
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
Thinking About Buying Stock In Moderna, Pinduoduo, Penn National Or Fiverr?
One of the most common questions traders have about stocks is “Why Is It Moving?”
That’s why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro. WIIMs are a one-sentence description as to why a stock is moving.
Oppenheimer Downgrades Moderna to Perform
Oppenheimer analyst Hartaj Singh downgrades Moderna (NASDAQ:MRNA) from Outperform to Perform.
Piper Sandler Downgrades Moderna to Neutral, Raises Price Target to $445
Piper Sandler analyst Edward Tenthoff downgrades Moderna (NASDAQ:MRNA) from Overweight to Neutral and raises the price target from $246 to $445.
Ocugen Stock Is Creeping Up To This Resistance Level
Ocugen Inc. (NASDAQ: OCGN) shares were trading higher Thursday in sympathy with other coronavirus vaccine stocks.
‘Fast Money Halftime Report’ Picks For August 5
On CNBC's "Fast Money Halftime Report," Jenny Harrington recommended a long position in Iron Mountain Inc (NYSE: IRM).